文献速递乳腺癌支持与姑息治疗

接受辅助化疗的早期乳腺癌患者中的治疗相关髓系肿瘤

Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
PubMed 文献 · Eur J Cancer · 2023-06-22

该研究基于韩国国家数据库纳入2007年1月至2016年10月间接受手术的153,565例乳腺癌患者,评估治疗相关急性髓系白血病(AML)/骨髓增生异常综合征(MDS)的累积发生率及危险因素。结果显示,含蒽环类辅助治疗组AML/MDS的10年累积发生率最高,且发生AML/MDS的风险显著高于未接受辅助化疗的对照组,风险至少持续10年。

要点

  • 含蒽环类辅助治疗组10年AML累积发生率为0.221%,MDS为0.199%,均为三组中最高。
  • 含蒽环类组发生AML的HR为9.531(p<0.0001),发生MDS的HR为2.559(p<0.0001),均以对照组为参照。
  • 尽管累积发生率低,但鉴于AML/MDS预后不良,应考虑其长期风险。

核心结论

  • 含蒽环类辅助治疗显著增加韩国乳腺癌患者发生AML/MDS的风险,且该风险至少持续10年。
  • 尽管累积发生率低,但鉴于AML/MDS预后不良,应考虑其长期风险。

研究设计与样本

  • 基于韩国国家数据库的队列研究,纳入2007年1月至2016年10月间诊断为乳腺癌并接受手术的患者153,565例。
  • 79,321例接受含蒽环类辅助治疗,14,317例接受不含蒽环类的辅助治疗,46,657例未接受辅助化疗。

主要发现

  • 共120例发生AML:含蒽环类组105例,不含蒽环类组9例,对照组6例。
  • 共128例发生MDS:含蒽环类组96例,不含蒽环类组9例,对照组23例。
  • AML的10年累积发生率:含蒽环类组0.221%,不含蒽环类组0.122%,对照组0.024%。
  • MDS的10年累积发生率:含蒽环类组0.199%,不含蒽环类组0.163%,对照组0.089%。
  • 与对照组相比,含蒽环类组发生AML的HR为9.531(p<0.0001),发生MDS的HR为2.559(p<0.0001)。

关键数值与推荐

  • 含蒽环类辅助治疗组AML的10年累积发生率为0.221%,MDS为0.199%。
  • 不含蒽环类辅助治疗组AML的10年累积发生率为0.122%,MDS为0.163%。
  • 未接受辅助化疗的对照组AML的10年累积发生率为0.024%,MDS为0.089%。
  • 含蒽环类组对比对照组:AML的HR为9.531(p<0.0001),MDS的HR为2.559(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term complications are becoming more important as the survival rate of breast cancer improves. Treatment-related myeloid neoplasm is an important long-term complication in breast cancer survivors as it has a poor prognosis. OBJECTIVE: We evaluated the incidence and risk factors for the development of treatment-related acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) in patients treated with early breast cancer. METHODS: We accessed the national Korean database to identify 153,565 patients diagnosed with breast cancer between January 2007 and October 2016 who underwent surgery for breast cancer. We estimated the cumulative incidence of AML/MDS and analysed the risk factors for developing AML/MDS. RESULTS: Of 153,575 patients, 79,321 received anthracycline-based adjuvant therapy, 14,317 received adjuvant therapy without anthracyclines and 46,657 did not receive adjuvant chemotherapy. Overall, 120 developed AML (105 in the anthracycline group, 9 in the non-anthracycline group and 6 in the control group), and 128 developed MDS (96, 9 and 23 in each group). The 10-year cumulative incidence of AML/MDS was the highest in the anthracycline group (0.221% and 0.199%), followed by the non-anthracycline group (0.122% and 0.163%) and the control group (0.024% and 0.089%). The risk of developing AML/MDS was significantly higher in patients treated with anthracyclines (hazard ratio [HR] 9.531; p < 0.0001 for AML and HR 2.559; p < 0.0001 for MDS) compared to patients in the control group. CONCLUSION: This study found that anthracycline-based adjuvant therapy significantly increased the risk of AML/MDS in Korean breast cancer patients, with the risk persisting for at least 10 years. While the cumulative incidence was low, the long-term risks of AML/MDS should be taken into account considering the poor outcomes associated with these neoplasms.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee JW, Oh H, You JY, et al. Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023. PMID: 37473463. doi:10.1016/j.ejca.2023.112952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。